Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
J Crohns Colitis. 2023 Jul 5;17(7):1154-1168. doi: 10.1093/ecco-jcc/jjad019.
With the recent acceptance of multiple treatment goals for inflammatory bowel diseases [IBD], it becomes increasingly important to accurately quantify the measurable concepts. These include patient-reported symptoms, intestinal damage, mucosal activity, transmural inflammation, and histologicl appearance, as well as quality of life, disability, and other patient-centred attributes. Standardised indices which show sufficient validity, reliability, and responsiveness to change are not only mandatory for implementing the treat to target approach but are also critical for assessing the effectiveness of emerging medications in clinical trial settings. Some concepts can be accurately assessed through the use of existing measurement tools used for adults [eg, capsule endoscopy, ultrasonic, endoscopic, and histological scoring] and others may be age specific. Although several paediatric indices and scales are well established (eg, IMPACT questionnaire, Paediatric Crohn's Disease Activity Index [PCDAI], and Paediatric Ulcerative Colitis Activity Index [PUCAI]), recent years have seen the development of newer indices for children, including the Mucosal Inflammation Noninvasive Index [MINI] to predict endoscopic healing in Crohn's disease, magnetic resonance imaging [MRI] indices that measure inflammation (ie, the Paediatric Inflammatory Crohn's Magnetic Resonance Enterography Index [PICMI]) and perianal disease (ie, Paediatric MRI-based Perianal Crohn's Disease [PEMPAC]), and patient-reported outcome measures in ulcerative colitis [ie, TUMMY-UC], upper gastrointestinal inflammatory score [ie, UGI-SES-CD], simplified endoscopic mucosal assessment score for Crohn's disease [SEMA-CD], and the parent-completed IMPACT questionnaire [ie, IMPACT-III-P]. Despite these advances, quantifiable paediatric IBD-specific tools are still lacking for disability and fatigue. In this review, we provide a contemporary, clinically focused overview of the indices that a paediatric gastroenterologist can use to quantify disease status.
随着人们最近接受了治疗炎症性肠病(IBD)的多个治疗目标,准确量化可衡量的概念变得越来越重要。这些概念包括患者报告的症状、肠道损伤、黏膜活性、透壁炎症和组织学外观,以及生活质量、残疾和其他以患者为中心的属性。不仅需要具有足够有效性、可靠性和对变化的反应能力的标准化指标来实施治疗目标方法,而且还需要这些指标来评估临床试验中新兴药物的有效性。一些概念可以通过使用现有的成人测量工具(例如胶囊内镜、超声、内镜和组织学评分)来准确评估,而其他概念可能具有年龄特异性。尽管已经建立了几个儿科指数和量表(例如,IMPACT 问卷、小儿克罗恩病活动指数[PCDAI]和小儿溃疡性结肠炎活动指数[PUCAI]),但近年来已经为儿童开发了新的指数,包括黏膜炎症无创指数[MINI]以预测克罗恩病的内镜愈合、测量炎症的磁共振成像[MRI]指数(即小儿炎症性克罗恩病 MRI 指数[PICMI])和肛周疾病(即基于 MRI 的小儿肛周克罗恩病[PEMPAC]),以及溃疡性结肠炎的患者报告结局测量[即,TUMMY-UC]、上消化道炎症评分[即,UGI-SES-CD]、简化克罗恩病内镜黏膜评估评分[SEMA-CD]和家长完成的 IMPACT 问卷[即,IMPACT-III-P]。尽管取得了这些进展,但仍然缺乏用于残疾和疲劳的可量化的儿科 IBD 特定工具。在这篇综述中,我们提供了一种当代的、以临床为重点的综述,介绍了儿科胃肠病学家可以用来量化疾病状态的指数。